Drug efficacy and cellular target engagement studies have traditionally been monitored by evaluation of downstream cellular responses, such as detection…
Read MoreSearch results: “Abl”
Showing 37–48 of 95 results
A common feature of 7TM receptors is that upon activation, the receptors are bound by cellular Arrestin proteins. DiscoveRx has…
Read MoreDiscoveRx’s PathHunter® platform is a simple, cell-based, chemiluminescent assay format that allows for screening large numbers of small molecules or…
Read MoreMonoclonal antibodies (MAbs) represent one of the fastest growing classes of biotherapeutic molecules today. While many technologies exist for generating…
Read MoreBiologics represents one of the fastest growing classes of biopharmaceutical molecules today. One of the major bottlenecks in the development…
Read MoreDiscoveRx has developed a panel of over 120 characterized GPCR cell lines that monitor receptor activity using interaction with human…
Read MoreLigand-induced receptor dimerization is an early functional step in receptor activation, representing the most proximal, functional read-out for Interleukin receptors.…
Read MoreKinase therapeutics includes both monoclonal antibodies (mAbs) and small-molecule inhibitors. DiscoveRx’s PathHunter® protein: protein interaction system uses well-established Enzyme Fragment…
Read MoreOrphan GPCRs continue to represent a target class with immense potential for the discovery of novel therapeutic compounds. In spite…
Read MoreCystic fibrosis (CF) patients have mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) chloride channel that result in reduced…
Read MoreThe clinical success of an ever-increasing array of biologics has led to the development of a wide spectrum of immunomodulatory…
Read MoreOne of the major bottlenecks in the development of biosimilars is the need for good bioassays to create potency, stability…
Read More